Pralsetinib
Sign in to save this workspacePrimary targets: RET · FDA status: FDA Approved
Selectivity scorecard
KISS
93.43
Gini
0.643
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pralsetinib. Strongest target: RET at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 100.0% | 0.0% |
| 2 | ERBB4_HER4 | 99.7% | 0.3% |
| 3 | TRKC | 99.4% | 0.6% |
| 4 | TRKB | 99.4% | 0.6% |
| 5 | EGFR | 99.1% | 0.9% |
| 6 | JAK1 | 99.1% | 0.9% |
| 7 | JAK2 | 99.1% | 0.9% |
| 8 | TRKA | 98.7% | 1.3% |
| 9 | JAK3 | 98.1% | 1.9% |
| 10 | FLT3 | 97.6% | 2.4% |
| 11 | ERBB2_HER2 | 97.5% | 2.5% |
| 12 | ROS_ROS1 | 97.3% | 2.7% |
| 13 | DDR1 | 96.9% | 3.1% |
| 14 | TYK2 | 96.8% | 3.2% |
| 15 | MLK3_MAP3K11 | 96.5% | 3.5% |
| 16 | FLT4_VEGFR3 | 96.5% | 3.5% |
| 17 | LIMK1 | 96.4% | 3.6% |
| 18 | BLK | 96.1% | 3.9% |
| 19 | DDR2 | 95.9% | 4.1% |
| 20 | C_KIT | 93.8% | 6.2% |
Selectivity landscape
Where Pralsetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pralsetinib.
Annotations
Sign in to read and post annotations.
Loading…